Xenon Pharmaceuticals XENE Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's retained earnings?
- Xenon Pharmaceuticals (XENE) reported retained earnings of -$1.35B in Q1 2026.
- How has Xenon Pharmaceuticals's retained earnings changed year-over-year?
- Xenon Pharmaceuticals's retained earnings decreased by 39.7% year-over-year, from -$964.52M to -$1.35B.
- What is the long-term trend for Xenon Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's retained earnings has grown at a 34.9% compound annual growth rate (CAGR), from -$278.49M to -$1.25B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.